This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Cadence Pharmaceuticals Inc. Q2 2010 Earnings Call Transcript

Cadence Pharmaceuticals Inc. (CADX)

Q2 2010 Earnings Call

August 05, 2010

Executives

Ted Schroeder - President and CEO

Jim Breitmeyer - EVP and Chief Medical Officer

Bill LaRue - EVP and CFO

Analysts

Charles Duncan - JMP Securities

Eric Schmidt - Cowen and Company

Adam Cutler - Canaccord

Greg Fraser - Banc of America-Merrill Lynch

John Newman - Oppenheimer

Presentation

Operator

Welcome to the Cadence Pharmaceuticals Second Quarter 2010 Financial Results Conference Call. On the call today are Ted Schroeder, President and CEO, Jim Breitmeyer, Executive Vice President and Chief Medical Officer, and Bill LaRue, Senior Vice President and Chief Financial Officer.

At this time, I would like to inform you that this conference is being recorded and that all participants are in a listen-only mode. (Operator Instruction)

Our first is speaker is Bill LaRue. Go ahead, sir.

Bill LaRue

Before we get started today, I would like to remind you that statements included in this conference call that are not a description of historical facts are forward-looking statements. Such forward-looking statements include statements regarding: the timeframe in which the FDA is expected to complete its review of our NDA for OFIRMEV, and our belief that our NDA will be sufficient for the FDA to approve this product candidate; our readiness to launch OFIRMEV, and the potential strength of any such launch; the sufficiency of the our capital resources to fund our operations through the approval of initial launch period of OFIRMEV; our ability to complete future drawdowns under our loan facility; the potential for us acquire Incline Therapeutics and the anticipated strategic benefit of any such acquisition, and all of our financial estimates and projections.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
CADX $0.00 0.00%
YHOO $44.47 0.00%
TSLA $190.41 0.00%
AAPL $124.24 0.00%
FB $83.01 0.00%

Markets

DOW 17,678.23 -40.31 -0.23%
S&P 500 2,056.15 -4.90 -0.24%
NASDAQ 4,863.3620 -13.1570 -0.27%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs